Attenuated antiaggregation effects of magnetite nanoparticles in cerebrospinal fluid of people with Alzheimer's disease
- 19 August 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Molecular BioSystems
- Vol. 6 (11) , 2200-2205
Abstract
It is well known that oligomeric/aggregated amyloid β peptides are a key player in the pathogenesis of Alzheimer's disease and that different nanoparticles influence oligomerization/aggregation processes in experiments in vitro. Our previous results demonstrated antiaggregation effects of magnetite nanoparticles in the case of protein lysozyme, however, they have yet to be supported by biological samples containing peptides/proteins preaggregated in vivo. In the study, Thioflavin T based fluorescence was evaluated on cerebrospinal fluid samples from people with Alzheimer's disease/multiple sclerosis and corresponding age-related controls using magnetite nanoparticles incubated for 24 h. Our results are as follows: (i) fluorescence of samples without nanoparticles was significantly higher in both older groups (old controls and people with Alzheimer's disease) than in those of younger (young controls and people with multiple sclerosis), (ii) nanoparticles did not markedly influence a fluorescence intensity in young people but eliminated it in both old groups; nevertheless, the effects of nanoparticles were significantly lower in patients with Alzheimer's disease then in the age-matched controls, and finally (iii) significant positive correlation was observed between fluorescence of samples without nanoparticles and levels of phospho-tau. Our results support studies reporting enhanced aggregation of different peptides/proteins occurring during normal aging and demonstrate for the first time that peptides/proteins preaggregated in vivo during Alzheimer's disease are more resistant to the antiaggregation effects of magnetite nanoparticles than those of age-matched controls. A significant correlation with phospho-tau levels indicate that the in vitro test with magnetite nanoparticles and Thioflavin T dye on cerebrospinal fluid could be sensitive to changes mediated by early Alzheimer's disease stages.Keywords
This publication has 26 references indexed in Scilit:
- Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-β fibrils detection and removal by a magnetic fieldBiochemical and Biophysical Research Communications, 2009
- Enhanced levels of mitochondrial enzyme17β-hydroxysteroid dehydrogenase type 10 in patients with Alzheimer disease and multiple sclerosisMolecular BioSystems, 2009
- CSF APPsα and Phosphorylated Tau Protein Levels in Mild Cognitive Impairment and Dementia of Alzheimer's TypeJournal of Geriatric Psychiatry and Neurology, 2008
- Effect of maghemite nanoparticles on insulin amyloid fibril formation: Selective labeling, kinetics, and fibril removal by a magnetic fieldJournal of Biomedical Materials Research Part A, 2008
- Nucleation of protein fibrillation by nanoparticlesProceedings of the National Academy of Sciences, 2007
- RETRACTED: Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α-synuclein fibril formation in vitroExperimental Neurology, 2007
- RETRACTED: Cerebrospinal fluid of Alzheimer patients promotes β-amyloid fibril formation in vitroNeurobiology of Disease, 2005
- Proteome analysis of cerebrospinal fluid proteins in Alzheimer patientsNeuroReport, 2002
- Comparison of methods for analysis of CSF proteins in patients with Alzheimer’s diseaseNeurochemical Pathology, 1987
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984